Cover Image
市場調查報告書

藥物安全檢測市場分析:各臨床實驗階段 (前臨床研究、第一階段、第二階段、第三階段、第四階段)、服務供應商 (內部、委託外包),及至2020年的市場區隔預測

Pharmacovigilance Market Analysis By Clinical Trial Phases (Preclinical Studies, Phase I/1, Phase II/2, Phase III/3, Phase IV/4 Trial), By Type Of Service Providers (In House, Contract Outsourcing) And Segment Forecasts To 2020

出版商 Grand View Research, Inc. 商品編碼 342335
出版日期 內容資訊 英文 102 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
藥物安全檢測市場分析:各臨床實驗階段 (前臨床研究、第一階段、第二階段、第三階段、第四階段)、服務供應商 (內部、委託外包),及至2020年的市場區隔預測 Pharmacovigilance Market Analysis By Clinical Trial Phases (Preclinical Studies, Phase I/1, Phase II/2, Phase III/3, Phase IV/4 Trial), By Type Of Service Providers (In House, Contract Outsourcing) And Segment Forecasts To 2020
出版日期: 2015年02月15日 內容資訊: 英文 102 Pages
簡介

全球藥物安全檢測市場預計至2020年達到55億1,000萬美元。對藥物的有害反應的發生率上升和嚴格的藥物安全性規定的引進等帶動市場擴大。預計委託外包領域到2020年以13.1%的成長率擴大。

本報告提供全球藥物安全檢測市場相關分析、各臨床實驗階段、服務供應商預測,及各地區趨勢等彙整資料。

第1章 摘要整理

第2章 藥物安全檢測產業預測

  • 市場區隔
  • 市場規模與成長預測
  • 市場趨勢
    • 促進要素
    • 阻礙要素
  • 被優先的機會
  • PESTEL分析
  • 市場佔有率分析:2013年

第3章 各臨床實驗階段預測

  • 各臨床實驗階段市場佔有率
  • 前臨床
  • 第0層
  • 第一階段
  • 第二階段
  • 第三階段
  • 第四階段

第4章 服務供應商預測

  • 服務供應商市場佔有率
  • 內部
  • 委託外包

第5章 各地區預測

  • 各地區市場佔有率:2013年、2020年
  • 北美
  • 歐洲
  • 亞太地區
  • 其他各國

第5章 競爭環境

  • Accenture Plc.
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb
  • Clinquest Group B.V.
  • Cognizant Technology Solutions Corporation
  • Covance, Inc.
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline (GSK)
  • IBM Corporation
  • ICON, Plc
  • iGATE Corporation
  • iMEDGlobal Corporation
  • Infosys
  • Ipca Laboratories Ltd
  • Janssen Research & Development, LLC
  • Novartis International AG
  • PAREXEL International Corporation
  • Pfizer, Inc.
  • Pharmaceutical Product Development, Inc. (PPD, Inc.)
  • Sanofi Aventis
  • Synowlwedge LLC
  • Wipro Ltd.
  • PRA Health Sciences Inc
  • Quantum Solutions India
  • Quintiles Transnational Corporation
  • inVentiv Health Inc.
  • OptumInsight, Inc.
  • United BioSource Corporation
  • Ecron Acunova
  • Fortitude Clinical
  • ITClinical

第7章 調查方法與調查範圍

圖表

目錄

Global pharmacovigilance market is expected to reach USD 5.51 billion by 2020. Increasing incidence rates of adverse drug reaction and the introduction of stringent drug safety regulations are some key drivers of this market. ADR is responsible for approximately 5% of the hospitalization in developed countries annually, and this is expected to boost usage rates over the next six years. Pharmacovigilance has witnessed a significant rise in usage rates in the recent times owing to growing global geriatric population triggering a growth in demand for new drug development. Additionally, health regulatory authorities such as the U.S. FDA and EMEA (European Medicines Agency) are now emphasizing on electronic submission of data which is also expected to drive the pharmacovigilance market.

Contract outsourcing pharmacovigilance market is expected to grow at a lucrative rate of over 13.1% during the forecast period. Service flexibility and cost effectiveness associated with outsourcing are some key factors accounting for the segment's lucrative growth.

Further key findings from the study suggest:

Pharmacovigilance services found the largest application in phase 4/IV clinical trial studies in 2013. Greater applicability and relevance are some factors accounting for the segment's market position.

Contract outsourcing was the most revenue generating service provider segment in 2013. Minimization of upfront investments and reduction in fixed overhead costs are some factors expected to drive segment growth.

North America was the largest regional market, accounting for over 40.0% of the revenue in 2013. Presence of stringent healthcare regulations implemented by the U.S. FDA and high market penetration rates of electronic medical records are some factors responsible for its large share.

Asia Pacific is identified as the most lucrative market. Presence of a large pool of skilled labor and favorable business environments are some factors expected to drive regional market growth. Rapidly improving healthcare infrastructure in the emerging economies of India and China is also expected to provide new growth opportunities to the market participants.

Key players of this market include Quintiles Transnational Corporation, PAREXEL International, Clinquest Group BV, Pharmaceutical Product Development, Accenture Plc., Boehringer Ingelheim GmbH and Cognizant Technology Solutions

Providing customized end to end PV solutions & services and entering into strategic agreements are some key strategies adopted by these market players.

For the purpose of this study, Grand View Research has segmented the pharmacovigilance market on the basis of clinical trial phase, type of service provider and region:

Global Pharmacovigilance Clinical Trial Phase Outlook (Revenue, USD Million, 2012 - 2020)

  • Pre Clinical
  • Phase 0
  • Phase 1/I
  • Phase 2/II
  • Phase 3/III
  • Phase 4/IV

Global Pharmacovigilance Service Provider Outlook (Revenue, USD Million, 2012 - 2020)

  • In- House
  • Contract Outsourcing

Pharmacovigilance Regional Outlook (Revenue, USD Million, 2012 - 2020)

  • North America
  • Europe
  • Asia Pacific
  • RoW

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Pharmacovigilance- Industry Summary and Critical Success Factors (CSFs)

Chapter 2. Pharmacovigilance Industry Outlook

  • 2.1. Market Segmentation
  • 2.2. Market Size and Growth Prospects
  • 2.3. Pharmacovigilance - Market dynamics
    • 2.3.1. Market Driver Analysis
    • 2.3.2. Market Restraint Analysis
  • 2.4. Key Opportunities Prioritized
  • 2.5. Pharmacovigilance - PESTEL Analysis
  • 2.6. Pharmacovigilance Company Market Share Analysis, 2013

Chapter 3. Pharmacovigilance Clinical Trial Phase Outlook

  • 3.1. Pharmacovigilance market share, by clinical trial phase, 2013 & 2020
  • 3.2. Preclinical
    • 3.2.1. Preclinical Market Estimates and Forecasts, 2012 - 2020 (USD Million)
  • 3.3. Phase 0
    • 3.3.1. Phase 0 Market Estimates and Forecasts, 2012 - 2020 (USD Million)
  • 3.4. Phase I
    • 3.4.1. Phase I Market Estimates and Forecasts, 2012 - 2020 (USD Million)
  • 3.5. Phase II
    • 3.5.1. Phase II Market Estimates and Forecasts, 2012 - 2020 (USD Million)
  • 3.6. Phase III
    • 3.6.1. Phase III Market Estimates and Forecasts, 2012 - 2020 (USD Million)
  • 3.7. Phase IV
    • 3.7.1. Phase IV Market Estimates and Forecasts, 2012 - 2020 (USD Million)

Chapter 4. Pharmacovigilance Type of Service Provider Outlook

  • 4.1. Pharmacovigilance market share, by type of service provider, 2013 & 2020
  • 4.2. In- House
    • 4.2.1. In-House Market Estimates and Forecasts, 2012 - 2020 (USD Million)
  • 4.3. Contract Outsourcing
    • 4.3.1. Contract Outsourcing Market Estimates and Forecasts, 2012 - 2020 (USD Million)

Chapter 5. Pharmacovigilance Regional Outlook

  • 5.1. Pharmacovigilance market share by region, 2012 & 2020
  • 5.2. North America
    • 5.2.1. Market Estimates and Forecasts, by Clinical Trial Phase
    • 5.2.2. Market Estimates and Forecasts, by Type of Service Provider
  • 5.3. Europe
    • 5.3.1. Market Estimates and Forecasts, by Clinical Trial Phase
    • 5.3.2. Market Estimates and Forecasts, by Type of Service Provider
  • 5.4. Asia Pacific
    • 5.4.1. Market Estimates and Forecasts, by Clinical Trial Phase
    • 5.4.2. Market Estimates and Forecasts, by Type of Service Provider
  • 5.5. RoW
    • 5.5.1. Market Estimates and Forecasts, by Clinical Trial Phase
    • 5.5.2. Market Estimates and Forecasts, by Type of Service Provider

Chapter 6. Competitive Landscape

  • 6.1 Accenture Plc.
    • 6.1.1. Company Overview
    • 6.1.2. Financial Performance
    • 6.1.3. Product Benchmarking
    • 6.1.4. Strategic Initiatives
  • 6.2. Boehringer Ingelheim GmbH
    • 6.2.1. Company Overview
    • 6.2.2. Financial Performance
    • 6.2.3. Product Benchmarking
    • 6.2.4. Strategic Initiatives
  • 6.3. Bristol-Myers Squibb
    • 6.3.1. Company Overview
    • 6.3.2. Financial Performance
    • 6.3.3. Product Benchmarking
    • 6.3.4. Strategic Initiatives
  • 6.4. Clinquest Group B.V.
    • 6.4.1. Company Overview
    • 6.4.2. Financial Performance
    • 6.4.3. Product Benchmarking
    • 6.4.4. Strategic Initiatives
  • 6.5. Cognizant Technology Solutions Corporation
    • 6.5.1. Company Overview
    • 6.5.2. Financial Performance
    • 6.5.3. Product Benchmarking
    • 6.5.4. Strategic Initiatives
  • 6.6. Covance, Inc.
    • 6.6.1. Company Overview
    • 6.6.2. Financial Performance
    • 6.6.3. Product Benchmarking
    • 6.6.4. Strategic Initiatives
  • 6.7. F. Hoffmann-La Roche Ltd
    • 6.7.1. Company Overview
    • 6.7.2. Financial Performance
    • 6.7.3. Product Benchmarking
    • 6.7.4. Strategic Initiatives
  • 6.8. GlaxoSmithKline (GSK)
    • 6.8.1. Company Overview
    • 6.8.2. Financial Performance
    • 6.8.3. Product Benchmarking
    • 6.8.4. Strategic Initiatives
  • 6.9. IBM Corporation
    • 6.9.1. Company Overview
    • 6.9.2. Financial Performance
    • 6.9.3. Product Benchmarking
    • 6.9.4. Strategic Initiatives
  • 6.10. ICON, Plc
    • 6.10.1. Company Overview
    • 6.10.2. Financial Performance
    • 6.10.3. Product Benchmarking
    • 6.10.4. Strategic Initiatives
  • 6.11. iGATE Corporation
    • 6.11.1. Company Overview
    • 6.11.2. Financial Performance
    • 6.11.3. Product Benchmarking
    • 6.11.4. Strategic Initiatives
  • 6.12. iMEDGlobal Corporation
    • 6.12.1. Company Overview
    • 6.12.2. Financial Performance
    • 6.12.3. Product Benchmarking
    • 6.12.4. Strategic Initiatives
  • 6.13. Infosys
    • 6.13.1. Company Overview
    • 6.13.2. Financial Performance
    • 6.13.3. Product Benchmarking
    • 6.13.4. Strategic Initiatives
  • 6.14. Ipca Laboratories Ltd
    • 6.14.1. Company Overview
    • 6.14.2. Financial Performance
    • 6.14.3. Product Benchmarking
    • 6.14.4. Strategic Initiatives
  • 6.15. Janssen Research & Development, LLC
    • 6.15.1. Company Overview
    • 6.15.2. Financial Performance
    • 6.15.3. Product Benchmarking
    • 6.15.4. Strategic Initiatives
  • 6.16. Novartis International AG
    • 6.16.1. Company Overview
    • 6.16.2. Financial Performance
    • 6.16.3. Product Benchmarking
    • 6.16.4. Strategic Initiatives
  • 6.17. PAREXEL International Corporation
    • 6.17.1. Company Overview
    • 6.17.2. Financial Performance
    • 6.17.3. Product Benchmarking
    • 6.17.4. Strategic Initiatives
  • 6.18. Pfizer, Inc.
    • 6.18.1. Company Overview
    • 6.18.2. Financial Performance
    • 6.18.3. Product Benchmarking
    • 6.18.4. Strategic Initiatives
  • 6.19. Pharmaceutical Product Development, Inc. (PPD, Inc.)
    • 6.19.1. Company Overview
    • 6.19.2. Financial Performance
    • 6.19.3. Product Benchmarking
    • 6.19.4. Strategic Initiatives
  • 6.20. Sanofi Aventis
    • 6.20.1. Company Overview
    • 6.20.2. Financial Performance
    • 6.20.3. Product Benchmarking
    • 6.20.4. Strategic Initiatives
  • 6.21. Synowlwedge LLC
    • 6.21.1. Company Overview
    • 6.21.2. Financial Performance
    • 6.21.3. Product Benchmarking
    • 6.21.4. Strategic Initiatives
  • 6.22. Wipro Ltd.
    • 6.22.1. Company Overview
    • 6.22.2. Financial Performance
    • 6.22.3. Product Benchmarking
    • 6.22.4. Strategic Initiatives
  • 6.23. PRA Health Sciences Inc.
    • 6.23.1. Company Overview
    • 6.23.2. Financial Performance
    • 6.23.3. Product Benchmarking
    • 6.23.4. Strategic Initiatives
  • 6.24. Quantum Solutions India
    • 6.24.1. Company Overview
    • 6.24.2. Financial Performance
    • 6.24.3. Product Benchmarking
    • 6.24.4. Strategic Initiatives
  • 6.25. Quintiles Transnational Corporation
    • 6.25.1. Company Overview
    • 6.25.2. Financial Performance
    • 6.25.3. Product Benchmarking
    • 6.25.4. Strategic Initiatives
  • 6.26. inVentiv Health Inc.
    • 6.26.1. Company Overview
    • 6.26.2. Financial Performance
    • 6.26.3. Product Benchmarking
    • 6.26.4. Strategic Initiatives
  • 6.27. OptumInsight, Inc.
    • 6.27.1. Company Overview
    • 6.27.2. Financial Performance
    • 6.27.3. Product Benchmarking
    • 6.27.4. Strategic Initiatives
  • 6.28. United BioSource Corporation
    • 6.28.1. Company Overview
    • 6.28.2. Financial Performance
    • 6.28.3. Product Benchmarking
    • 6.28.4. Strategic Initiatives
  • 6.29. Ecron Acunova
    • 6.29.1. Company Overview
    • 6.29.2. Financial Performance
    • 6.29.3. Product Benchmarking
    • 6.29.4. Strategic Initiatives
  • 6.30. Fortitude Clinical
    • 6.30.1. Company Overview
    • 6.30.2. Financial Performance
    • 6.30.3. Product Benchmarking
    • 6.30.4. Strategic Initiatives
  • 6.31. ITClinical
    • 6.31.1. Company Overview
    • 6.31.2. Financial Performance
    • 6.31.3. Product Benchmarking
    • 6.31.4. Strategic Initiatives

Chapter 7. Methodology and Scope

  • 7.1. Research Methodology
  • 7.2. Research Scope & Assumption
  • 7.3. List of Data Sources

List of Tables

  • 1. Pharmacovigilance Market - Industry Summary & Critical Success Factors (CSFs)
  • 2. Global Pharmacovigilance Market Revenue, By Clinical Trial Phase, 2012 - 2020, Revenue (USD Million)
  • 3. Global Pharmacovigilance Market Revenue, By Type of Service Provider , 2012 - 2020, Revenue (USD Million)
  • 4. Global Pharmacovigilance Market Revenue, By Region, 2012 - 2020, Revenue (USD Million)
  • 5. Pharmacovigilance Market - Key market driver analysis
  • 6. Pharmacovigilance - Key market restraint analysis
  • 7. North America Pharmacovigilance Market Size And Trends, 2012 - 2020, Revenue (USD Million)
  • 8. North America Pharmacovigilance Market Revenue, By Clinical Trial Phase, 2012 - 2020 (USD Million)
  • 9. North America Pharmacovigilance Market Revenue, By Type of Service provider, 2012 - 2020 (USD Million)
  • 10. Europe Pharmacovigilance Market Size And Trends, 2012 - 2020, Revenue (USD Million)
  • 11. Europe Pharmacovigilance Market Revenue, By Clinical Trial Phase, 2012 - 2020 (USD Million)
  • 12. Europe Pharmacovigilance Market Revenue, By Type of service Provider, 2012 - 2020 (USD Million)
  • 13. Asia Pacific Pharmacovigilance Market Size And Trends, 2012 - 2020, Revenue (USD Million)
  • 14. Asia Pacific Pharmacovigilance Market Revenue, By Clinical Trial Phase, 2012 - 2020 (USD Million)
  • 15. Asia Pacific Pharmacovigilance Market Revenue, By Type of service Provider, 2012 - 2020 (USD Million)
  • 16. RoW Pharmacovigilance Market Size And Trends, 2012 - 2020, Revenue (USD Million)
  • 17. RoW Pharmacovigilance Market Revenue, By Clinical Trial Phase, 2012 - 2020 (USD Million)
  • 18. RoW Pharmacovigilance Market Revenue, By Type of Service Provider, 2012 - 2020 (USD Million)

List of Figures

  • 1. Pharmacovigilance: Market Segmentation
  • 2. Global Pharmacovigilance Market, 2012 - 2020, Revenue (USD Million)
  • 3. Pharmacovigilance Market Dynamics
  • 4. Key Opportunities Prioritized
  • 5. Pharmacovigilance Market - Porter's Analysis
  • 6. Pharmacovigilance Market - PESTEL Analysis
  • 7. Pharmacovigilance Company Market Share Analysis, 2013
  • 8. Pharmacovigilance Market Share, By Clinical Trial Phase, 2013 & 2020
  • 9. Pharmacovigilance Market Share, By Type of Service Provider, 2013 & 2020
  • 10. Pharmacovigilance Market Share, By Region, 2013 & 2020
Back to Top